Loading organizations...
Prebys Ventures Fund operates as an impact investment fund, dedicated to fostering the innovation economy within the San Diego region. It systematically identifies, invests in, and nurtures promising tech and life sciences companies across both early and growth stages. The fund employs a distinct financial model, channeling all investment returns back into the local economy, thereby establishing a self-sustaining vehicle for perpetual investment within the San Diego community.
This initiative was launched by the Prebys Foundation, formally announced on February 12, 2025, with the strategic aim of addressing a notable funding gap in San Diego’s entrepreneurial landscape. Mike Krenn, an established figure in the local startup ecosystem and former CEO of Connect San Diego, was appointed to lead the fund as its Managing Director. His extensive background in cultivating innovation and facilitating capital raises underscored the foundation's commitment to experienced leadership.
Prebys Ventures primarily serves San Diego-based tech and life sciences companies, alongside the broader regional community, by stimulating economic growth and job creation. The fund's overarching vision is to solidify San Diego’s position as a global innovation hub, striving to deliver both robust financial performance and tangible positive societal impact, thus creating lasting opportunities for its local communities.
Prebys Ventures Fund has 3 tracked investments across 3 companies. The latest tracked deal is $24.0M Series A in Condor Software, Inc. in March 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 18, 2026 | Condor Software, Inc. | $24.0M Series A | Alex Leibowitz | 645 Ventures, Bramalea Partners, Felicis Ventures, Pamir Ventures, SNR |
| Nov 20, 2025 | Aspen Neuroscience | $115.0M Series C | ARCH Venture Partners, Frazier Life Sciences, OrbiMed, Revelation Partners | Axon Ventures, Balyasny Asset Management, Cormorant Asset Management, Cindy Perettie, LifeForce Capital, Lyfe Capital, Medical Excellence Capital, Section 32 |
| Sep 30, 2025 | Crystalys Therapeutics | $205.0M Series A | Ashwin RAM, Novo Holdings, SR ONE | Abrdn, Alexandria Venture Investments, AN Ventures, KB Investment, Lightstone Ventures, Longwood Fund, Perceptive Xontogeny Venture Fund, Pontifax, Wedbush Healthcare Partners |